It was not until the advent of antibodies to PSMA and thereafter the introduction of PSMA PET-CT, have we been able to identify localised prostate cancer with sufficient accuracy and avoid excessive and unnecessary prostatic biopsies. This evidence concerns the gene FOLH1 and prostate carcinoma.